Drug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies

Stock News

08/12

Shanghai Haoyuan Chemexpress Co.,Ltd. (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.

Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1181412602"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181412602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181412602?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-12 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181412602","market":"sg","top_or_hot":-1,"title":"Drug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies","media":"Stock News","content":"<p><b>Shanghai Haoyuan Chemexpress Co.,Ltd.</b> (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.<br><br>Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-08-12 18:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>Shanghai Haoyuan Chemexpress Co.,Ltd.</b> (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.<br><br>Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多標普生物-Direxion","start_time":0,"source_url":"","article_id":"1181412602","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181412602","pubTimestamp":1786530782,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Haoyuan Chemexpress Co.,Ltd. (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688131":"皓元医药","LABU":"三倍做多标普生物-Direxion","BK0216":"研究试验","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"上海浩源化学快递药品生产基地零缺陷通过美国FDA检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688131":1,"LABU":1},"content_text":"Shanghai Haoyuan Chemexpress Co.,Ltd. (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}